The agency warned healthcare providers against giving remdesivir to patients at the same time as hydroxychloroquine or chloroquine, saying the combination could result in the “reduced antiviral activity of remdesivir.”
The FDA withdrew its emergency use authorizations for hydroyxychloroquine and chloroquine June 15 because research hasn’t proven them to be effective in preventing or treating COVID-19.
The agency updated the fact sheet for remdesivir with the new warning as well as with information about possible allergic reactions.
Read the FDA’s full news release here.
More articles on pharmacy:
FDA rescinds hydroxychloroquine emergency use authorization
6 recent drug, device recalls
10 exec moves affecting the pharma industry
